Standout Papers

Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor ... 2006 2026 2012 2019 1.1k
  1. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function (2006)
    Vassilios Papadopoulos, Mario Baraldi et al. Trends in Pharmacological Sciences
  2. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study (2016)
    Robin Carhart‐Harris, Mark Bolstridge et al. The Lancet Psychiatry
  3. Drug harms in the UK: a multicriteria decision analysis (2010)
    David Nutt, Leslie A. King et al. The Lancet
  4. Development of a rational scale to assess the harm of drugs of potential misuse (2007)
    David Nutt, Leslie A. King et al. The Lancet
  5. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin (2012)
    Robin Carhart‐Harris, David Erritzøe et al. Proceedings of the National Academy of Sciences
  6. Sleep disorders as core symptoms of depression (2008)
    David Nutt, Sue Wilson et al. Dialogues in Clinical Neuroscience
  7. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology (2014)
    David S. Baldwin, Ian Anderson et al. Journal of Psychopharmacology
  8. The dopamine theory of addiction: 40 years of highs and lows (2015)
    David Nutt, Anne Lingford‐Hughes et al. Nature reviews. Neuroscience
  9. Homological scaffolds of brain functional networks (2014)
    Giovanni Petri, Paul Expert et al. Journal of The Royal Society Interface
  10. Increased Global Functional Connectivity Correlates with LSD-Induced Ego Dissolution (2016)
    Enzo Tagliazucchi, Leor Roseman et al. Current Biology
  11. Increased global integration in the brain after psilocybin therapy for depression (2022)
    Richard E. Daws, Christopher Timmermann et al. Nature Medicine
  12. Human brain effects of DMT assessed via EEG-fMRI (2023)
    Christopher Timmermann, Leor Roseman et al. Proceedings of the National Academy of Sciences

Immediate Impact

8 by Nobel laureates 11 from Science/Nature 101 standout
Sub-graph 1 of 21

Citing Papers

Mechanisms of long COVID and the path toward therapeutics
2024 Standout
Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study
2023 Standout
32 intermediate papers

Works of David Nutt being referenced

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
2016 Standout
Increased Global Functional Connectivity Correlates with LSD-Induced Ego Dissolution
2016 Standout
and 21 more

Author Peers

Author Last Decade Papers Cites
David Nutt 10918 4980 4560 7805 5864 677 32.2k
Dennis L. Murphy 17118 4034 4022 9394 7008 570 40.4k
Philip J. Cowen 8133 6331 6444 3963 7737 603 28.4k
Joanna S. Fowler 19016 2848 3852 5277 12761 471 46.3k
Robert M. Post 6805 3251 4001 6312 6772 569 36.1k
J. John Mann 9405 4092 6432 15119 6444 623 45.4k
Guy M. Goodwin 4522 6384 5326 6377 8774 469 33.8k
Harriet de Wit 12977 4345 4281 5719 7548 430 28.2k
Siegfried Kasper 4990 6126 7744 4865 5479 1.0k 33.7k
Ross J. Baldessarini 5329 1774 4095 6144 2643 611 29.4k
John M. Kane 4838 3695 5684 9441 5813 913 51.0k

All Works

Loading papers...

Rankless by CCL
2026